Vimarsana
Biggest News Aggregation in the World

Physician Lead News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Physician Lead. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Physician Lead Today - Breaking & Trending Today

Electronic Referral System Expands to Include MRIs, Ultrasounds - Vimarsana News

Electronic Referral System Expands to Include MRIs, Ultrasounds

News releases from the Government of Nova Scotia

Encompass welcomes local midwives to pregnancy care team | Cranbrook, East Kootenay, Ktunaxa Nation - Vimarsana News

Encompass welcomes local midwives to pregnancy care team | Cranbrook, East Kootenay, Ktunaxa Nation

Encompass welcomes local midwives to pregnancy care team

Source: e-know.ca
Prince George's Dr. Ingrid Cosio earns family doctor award - Vimarsana News

Prince George's Dr. Ingrid Cosio earns family doctor award

"Dr. Cosio puts you at ease, makes you feel like no question is a stupid one, and is genuinely interested in you as a person.”

Patients may be at higher risk of overdose when opioid therapy for pain is discontinued - Vimarsana News

Patients may be at higher risk of overdose when opioid therapy for pain is discontinued

Discontinuing opioids prescribed for chronic pain was associated with increased risk of overdose, according to a new study from the BC Centre on Substance Use and University of British Columbia-Okanagan published today in PLOS Medicine

SELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer - Vimarsana News

SELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer

- Median Overall Survival for GPS Combination was 18.4 Months Compared to 13.8 months in a Checkpoint Inhibitor Single Agent Study in a Similar Patient Population Treated with Checkpoint Inhibitor... | November 10, 2022